Publications by authors named "Anna M Sobieraj"

Article Synopsis
  • Scientists are having a tough time treating infections caused by certain bacteria because these bacteria are becoming resistant to common medicines.
  • A special type of enzyme called peptidoglycan hydrolases can help fight these bacteria, as they work quickly without worrying about resistance.
  • The researchers are working on a way to make these enzymes target the exact spot of the infection in bones, even helping to reach bacteria that hide inside cells, to improve treatment.
View Article and Find Full Text PDF

is a human pathogen causing life-threatening diseases. The increasing prevalence of multidrug-resistant infections is a global health concern, requiring development of novel therapeutic options. Peptidoglycan-degrading enzymes (peptidoglycan hydrolases, PGHs) have emerged as a highly effective class of antimicrobial proteins against and other pathogens.

View Article and Find Full Text PDF

We present an automated point-of-care testing (POCT) system for rapid detection of species- and resistance markers in methicillin-resistant Staphylococcus aureus (MRSA) at the level of single cells, directly from nasal swab samples. Our novel system allows clear differentiation between MRSA, methicillin-sensitive S. aureus (MSSA) and methicillin-resistant coagulase-negative staphylococci (MR-CoNS), which is not the case for currently used real-time quantitative PCR based systems.

View Article and Find Full Text PDF

is a major concern in human health care, mostly due to the increasing prevalence of antibiotic resistance. Intracellular localization of plays a key role in recurrent infections by protecting the pathogens from antibiotics and immune responses. Peptidoglycan hydrolases (PGHs) are highly specific bactericidal enzymes active against both drug-sensitive and -resistant bacteria.

View Article and Find Full Text PDF

The increasing number of multidrug-resistant bacteria intensifies the need to develop new antimicrobial agents. Endolysins are bacteriophage-derived enzymes that degrade the bacterial cell wall and hold promise as a new class of highly specific and versatile antimicrobials. One major limitation to the therapeutic use of endolysins is their often short serum circulation half-life, mostly due to kidney excretion and lysosomal degradation.

View Article and Find Full Text PDF